CERS
Cerus Corporation NASDAQ Listed Jan 31, 1997$2.63
+1.15%
vs $2.60
Mkt Cap $527.0M
52w Low $1.15
74.0% of range
52w High $3.15
50d MA $2.44
200d MA $2.02
P/E (TTM)
—
EV/EBITDA
380.8x
P/B
7.7x
Debt/Equity
1.5x
ROE
-24.3%
P/FCF
58.8x
RSI (14)
38.20
ATR (14)
$0.17
Beta
1.63
50d MA
$2.44
200d MA
$2.02
Avg Volume
2.4M
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
1220 Concord Avenue · Concord, CA 94520 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | -0.03 | -0.01 | +66.7% | 2.03 | +32.5% | +34.0% | +0.0% | -4.8% | +0.0% | +0.8% | — |
| Mar 2, 2026 | AMC | -0.01 | -0.01 | +0.0% | 2.53 | -15.4% | -15.8% | +5.2% | -8.9% | -5.4% | +0.0% | — |
| Nov 6, 2025 | AMC | -0.02 | -0.00 | +99.5% | 1.41 | +1.4% | +21.3% | -6.4% | +3.1% | +0.0% | -3.0% | — |
| Aug 5, 2025 | AMC | -0.02 | -0.03 | -50.0% | 1.28 | +0.0% | +0.8% | -3.9% | -2.4% | +3.3% | +3.2% | — |
| May 1, 2025 | AMC | -0.05 | -0.04 | +20.0% | 1.30 | -1.5% | +3.8% | -3.7% | -3.8% | +4.0% | +4.6% | — |
| Feb 20, 2025 | AMC | -0.01 | -0.01 | +0.0% | 1.74 | +1.7% | -5.2% | -0.6% | -0.6% | +0.6% | -3.0% | — |
| Oct 30, 2024 | AMC | -0.01 | -0.02 | -33.3% | 1.72 | +4.7% | -8.7% | -3.2% | +2.6% | +6.4% | +9.0% | — |
| Aug 1, 2024 | AMC | -0.02 | -0.03 | -25.0% | 2.04 | +5.4% | +15.2% | -5.5% | -1.4% | -4.6% | +4.3% | — |
| May 2, 2024 | AMC | -0.05 | -0.05 | -7.1% | 1.76 | +3.4% | -8.0% | +10.5% | +3.4% | +1.6% | +1.6% | — |
| Mar 5, 2024 | AMC | -0.01 | -0.01 | -58.5% | 1.99 | +7.5% | +21.6% | -1.7% | -5.0% | -3.1% | -2.3% | — |
| Nov 2, 2023 | AMC | -0.05 | -0.03 | +40.0% | 1.59 | +2.5% | +8.8% | -1.7% | +1.8% | -3.5% | -7.8% | — |
| Aug 2, 2023 | AMC | -0.05 | -0.07 | -40.0% | 2.98 | -8.2% | -18.0% | -0.4% | -9.7% | -6.8% | -4.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | BTIG | Upgrade | Neutral → Buy | — | $2.03 | $2.69 | +32.5% | +34.0% | +0.0% | -4.8% | +0.0% | +0.8% |
| May 1 | BTIG Research | Upgrade | Neutral → Buy | $4 | $2.03 | $2.69 | +32.5% | +34.0% | +0.0% | -4.8% | +0.0% | +0.8% |
| Feb 21 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.74 | $1.77 | +1.7% | -5.2% | -0.6% | -0.6% | +0.6% | -3.0% |
| Oct 17 | Stifel | Maintains | Buy → Buy | — | $1.80 | $1.63 | -9.4% | -9.4% | +4.3% | -1.2% | -3.0% | -1.2% |
| May 3 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.76 | $1.82 | +3.4% | -8.0% | +10.5% | +3.4% | +1.6% | +1.6% |
| Mar 7 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $2.42 | $2.50 | +3.3% | -1.7% | -5.0% | -3.1% | -2.3% | -5.1% |
| Mar 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.99 | $2.14 | +7.5% | +21.6% | -1.7% | -5.0% | -3.1% | -2.3% |
| Jan 20 | BTIG | Downgrade | Buy → Neutral | — | $3.10 | $3.14 | +1.3% | +0.6% | +0.0% | +0.0% | -0.6% | +0.0% |
| May 27 | Stifel | Maintains | Buy → Buy | — | $5.96 | $6.07 | +1.8% | -0.2% | +2.2% | +2.3% | +4.3% | -1.2% |
| Apr 16 | Stephens & Co. | Maintains | Overweight → Overweight | — | $5.03 | $5.08 | +1.0% | +2.2% | +2.5% | +3.2% | -5.3% | +3.3% |
| Feb 26 | BTIG Research | Maintains | Buy → Buy | — | $4.90 | $5.07 | +3.5% | +7.1% | -1.3% | -0.8% | -0.7% | -1.5% |
| Feb 26 | BTIG | Maintains | Buy → Buy | — | $4.90 | $5.07 | +3.5% | +7.1% | -1.3% | -0.8% | -0.7% | -1.5% |
| Nov 13 | BTIG Research | Upgrade | Neutral → Buy | — | $4.28 | $4.51 | +5.4% | +0.7% | +0.7% | +3.0% | -2.2% | -1.1% |
| Nov 13 | BTIG | Upgrade | Neutral → Buy | — | $4.28 | $4.51 | +5.4% | +0.7% | +0.7% | +3.0% | -2.2% | -1.1% |
| Aug 28 | Stifel | Maintains | Buy → Buy | — | $5.21 | $5.35 | +2.7% | +2.3% | +0.0% | +0.8% | -1.7% | -4.7% |
| Apr 22 | BTIG Research | Maintains | Buy → Buy | — | $6.65 | $6.75 | +1.5% | +0.0% | -2.6% | -0.5% | +0.3% | -0.8% |
| Apr 22 | BTIG | Maintains | Buy → Buy | — | $6.65 | $6.75 | +1.5% | +0.0% | -2.6% | -0.5% | +0.3% | -0.8% |
| Dec 17 | Wedbush | Downgrade | Outperform → Neutral | — | $6.59 | $6.34 | -3.8% | -10.0% | -0.5% | -0.7% | -1.5% | +3.8% |
| Apr 24 | BTIG Research | Maintains | Buy → Buy | — | $4.58 | $4.65 | +1.4% | +4.5% | -1.9% | -3.8% | -1.3% | -0.4% |
| Feb 27 | Cantor Fitzgerald | Maintains | Buy → Buy | — | $5.35 | $5.16 | -3.6% | -10.7% | -6.6% | -0.4% | +0.5% | -0.2% |
| Dec 2 | MLV & Co. | Maintains | Buy → Buy | — | $4.29 | $4.31 | +0.5% | -0.7% | -0.7% | +0.2% | +1.7% | +0.0% |
| May 5 | Cantor Fitzgerald | Maintains | Buy → Buy | — | $3.84 | $3.88 | +1.0% | +7.6% | -4.6% | -2.0% | -1.6% | +2.4% |
| Sep 30 | Wedbush | Maintains | Outperform → Outperform | — | $6.34 | $6.28 | -0.9% | +6.0% | +1.0% | +1.8% | -1.0% | +0.1% |
| Mar 1 | McNicoll Lewis Vlak | Maintains | Buy → Buy | — | $3.29 | $3.49 | +6.1% | +11.2% | +7.9% | +1.3% | +1.8% | +3.2% |
| Feb 7 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.18 | $3.17 | -0.3% | -0.6% | -1.3% | -0.6% | -1.9% | -1.0% |
| Oct 8 | TD Cowen | Maintains | Outperform → Outperform | — | $3.36 | $3.47 | +3.3% | +2.4% | -1.2% | +0.9% | -0.3% | -0.6% |
| Apr 17 | Cantor Fitzgerald | Maintains | Buy → Buy | — | $3.65 | $3.73 | +2.2% | +5.8% | -2.3% | +2.1% | +1.0% | -2.6% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | BJERKHOLT ERIC | — | Sell | 20,454 | $2.60 | $53K | 261,679 | -1.16% | +5.06% |
| May 29, 2026 | Jayaraman Vivek K | Chief Operating Officer | Sell | 16,667 | $3.00 | $50K | 1,656,707 | -1.48% | -0.77% |
| May 1, 2026 | Jayaraman Vivek K | Chief Operating Officer | Sell | 16,667 | $3.00 | $50K | 1,673,374 | +0.00% | +1.19% |
8-K · 5.02
!!! Very High
Cerus Corporation -- 8-K 5.02: Executive Change
Jun 3
8-K
Cerus Corporation -- 8-K Filing
Cerus Corporation raised 2025 product revenue guidance and outlined multiple 2026 catalysts including European INTERCEPT RBC regulatory decision and U.S. Phase 3 RedeS trial results, positioning for potential significant commercial expansion.
Apr 30
8-K · 5.02
!!! Very High
Cerus Corp -- 8-K 5.02: Executive Change
Cerus Corp lost two board members with the resignations of Kevin D. Green and Chrystal N. Jensen as directors.
Apr 21
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
CERS's change in executive leadership could signal strategic shifts in operations or performance concerns, making it crucial for investors to assess whether the new direction strengthens competitive positioning.
Mar 16
8-K
Cerus Corp -- 8-K Filing
Cerus Corp achieved record 2025 kit shipments for its INTERCEPT blood safety system, treating an estimated 600,000 patients globally and demonstrating strong commercial execution.
Mar 2
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Ark Investment Management Llc | 19,161,148 | $35M | Added | Mar 2026 |
| 2 | Soleus Capital Management, L.p. | 10,753,700 | $20M | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 8,131,778 | $15M | New | Mar 2026 |
| 4 | Wasatch Advisors Lp | 5,281,136 | $10M | Reduced | Mar 2026 |
| 5 | Morgan Stanley | 3,880,314 | $8M | Added | Dec 2025 |
| 6 | D.e. Shaw & Co | 3,731,151 | $7M | Reduced | Mar 2026 |
| 7 | Acadian Asset Management Llc | 3,709,501 | $7M | Added | Mar 2026 |
| 8 | Silverarc Capital Management, Llc | 2,814,383 | $6M | Added | Dec 2025 |
| 9 | Two Sigma Investments, Lp | 2,745,021 | $5M | Added | Mar 2026 |
| 10 | Ieq Capital, Llc | 2,443,241 | $4M | Added | Mar 2026 |
| 11 | Aqr Capital Management Llc | 2,113,232 | $4M | Added | Mar 2026 |
| 12 | Ubs Group Ag | 2,099,353 | $4M | Added | Mar 2026 |
| 13 | Vanguard Portfolio Management Llc | 1,919,067 | $3M | New | Mar 2026 |
| 14 | Northern Trust Corp | 1,485,090 | $3M | Added | Mar 2026 |
| 15 | Voya Investment Management Llc | 1,194,535 | $2M | Reduced | Dec 2025 |
| 16 | Assenagon Asset Management S.a. | 1,251,093 | $2M | Reduced | Mar 2026 |
| 17 | Bank Of America Corp /de/ | 1,218,330 | $2M | Added | Mar 2026 |
| 18 | Fmr Llc | 1,205,737 | $2M | Added | Mar 2026 |
| 19 | Iq Eq Fund Management (Ireland) Ltd | 746,067 | $2M | Added | Dec 2025 |
| 20 | Primecap Management Co/ca/ | 789,300 | $1M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$527.0M
Enterprise Value
$453.2M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.99x
P/B
7.71x
P/S
2.25x
P/FCF
58.82x
EV/EBITDA
380.85x
Shares Out
190.6M
Financials (TTM)
Revenue
$222.8M
Net Income
-$9.6M
EBITDA
$1.2M
Free Cash Flow
$8.5M
Op Cash Flow
$11.4M
EPS Basic
$-0.08
EPS Diluted
$-0.05
EPS Forward
$-0.07
Gross Margin
54.3%
Op Margin
-7.9%
Net Margin
-4.3%
Balance Sheet
Total Assets
$221.9M
Total Liab.
$156.9M
Total Equity
$65.0M
Cash
$82.9M
LT Debt
$40.5M
Book Value/Sh
$0.34
Debt/Equity
1.51x
Current Ratio
1.73
Quick Ratio
1.17
Returns & Growth
ROE
-24.3%
ROA
-7.0%
ROIC
-5.2%
Rev Growth YoY
+14.3%
EPS Growth YoY
+25.4%
Price Returns
2W
+21.1%
1M
+49.8%
3M
+18.8%
6M
+72.7%
12M
+139.4%
Technicals
52W High
$3.15
52W Low
$1.15
50d MA
$2.44
200d MA
$2.02
RSI (14)
38.20
ATR (14)
$0.17
Beta
1.63
Avg Volume
2.4M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$4.00
High
$5.00
Low
$3.00
Median
$4.00
Data updated apr 25, 2026 12:47am
· Source: financialmodelingprep.com